1. Home
  2. TTRX vs NHIV Comparison

TTRX vs NHIV Comparison

Compare TTRX & NHIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$16.25

Market Cap

298.8M

Sector

Health Care

ML Signal

HOLD

NHIV

NewHold Investment Corp IV Class A Ordinary Shares

N/A

Current Price

$10.05

Market Cap

276.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TTRX
NHIV
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
298.8M
276.5M
IPO Year
2025
2026

Fundamental Metrics

Financial Performance
Metric
TTRX
NHIV
Price
$16.25
$10.05
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
91.4K
5.6K
Earning Date
05-31-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$9.96
52 Week High
$14.50
$10.16

Technical Indicators

Market Signals
Indicator
TTRX
NHIV
Relative Strength Index (RSI) 75.45 44.81
Support Level $3.49 N/A
Resistance Level N/A $10.16
Average True Range (ATR) 1.31 0.01
MACD 0.32 -0.01
Stochastic Oscillator 88.29 0.00

Price Performance

Historical Comparison
TTRX
NHIV

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

About NHIV NewHold Investment Corp IV Class A Ordinary Shares

NewHold Investment Corp IV is a blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: